Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Year: 2023
Type: review
Source: Nature Reviews Clinical Oncology
Institutions: Henry Dunant Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, Maastricht University Medical Centre, Complexo Hospitalario Universitario A Coruña, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Antwerp University Hospital, Sidney Kimmel Comprehensive Cancer Center, Université Paris-Saclay, Sarah Cannon, German Center for Lung Research, LungenClinic Grosshansdorf, Centre Hospitalier Universitaire Vaudois, University of Lausanne
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune checkpoint inhibitors, resectable non-small cell lung cancer, early-stage lung cancer, neoadjuvant immunotherapy, adjuvant immunotherapy, perioperative immunotherapy, pathological response, predictive biomarkers, minimal residual disease, event-free survival, disease-free survival, overall survival, curative intent
Open Access status: bronze
OpenAlex ID: W4385199630
